Development and evaluation of a novel chromium III-based compound for potential inhibition of emerging SARS-CoV-2 variants

Development and evaluation of a novel chromium III-based compound for potential inhibition of emerging SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused 403 million cases of coronavirus disease (COVID-19) and resulted in more than 5.7 million deaths worldwide. Extensive research has identified several potential drug treatments for COVID-19. However, the development of new compou...

Full description

Bibliographic Details
Main Authors: Yu-Jung Lin, Navaneethan Sundhar, Hema Sri Devi, Hsueh-Fa Pien, Shina Fong-Mei Wen, Jenn-Line Sheu, Bruce Chi-Kang Tsai, Chih-Yang Huang
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Heliyon
Subjects:
COVID-19
ACE2
TMPRSS2
Chromium (III)-Based compound
SARS-CoV-2
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023072195

Similar Items

Similar Items